{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000328","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.889689+00:00","generated_at":"2026-06-05T05:22:05.303552+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1","bullets":["FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.","Trial HYPER-H23-1 is a randomized, double-blind, placebo-controlled study of DehydraTECH-CBD in Stage 1 or Stage 2 hypertension.","Clinical trial commencement is contingent on Lexaria raising sufficient funding.","FDA review completion marks a key milestone for Lexaria's DehydraTECH-CBD program."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000328","json":"https://secwatch.observer/filing/0001640334-24-000328.json","markdown":"https://secwatch.observer/filing/0001640334-24-000328.md","text":"https://secwatch.observer/filing/0001640334-24-000328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000328/0001640334-24-000328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000328/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:22:05.303552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}